Access Pharma (ACCP.OB) Product Development Update – Sponsored Post
Access Pharmaceuticals (OTC: ACCP.OB, “Access”) develops and commercializes products for the treatment and supportive care of cancer patients.
Profiles
A Busy Year for HydraDx
The economy is tough for biotech start-ups, but the CEO of HydraDx is feeling confident.
Dimera Fights the “Silent Killer”
According to the American Heart Association, heart disease is the number one killer of women over age 25–more than the next five causes of death, or all forms of cancer, combined.
Less-Invasive Spinal Surgery with Trinity Orthopedics
The San Diego-based company aims to reduce the incidence of complications resulting from lumbar spinal surgery, such as nerve damage or degeneration of adjacent discs.
Ovatech Leaves the Hormones Out of Birth Control
Ovatech of Auburndale, Mass., is developing the world’s first non-hormonal, female-controlled contraception device.
HealthLink Europe Provides Compass to Companies Looking to Go Overseas
HealthLink Europe help medical device and pharmaceutical manufacturers enter the European market by offering a full range of distribution-related services.
Pressure BioSciences Aims for Improved Sample Preparation
Pressure BioSciences seeks to improve sample yield with its novel technology platform, known as pressure cycling technology (PCT).
For Advaxis, Bacteria Help More Than They Hurt
The idea of using harmful bacteria to treat disease might strike many as an odd concept.
CytRx Puts Its Cancer Pipeline to the Test
All told, the Los Angeles-based company could have six to eight trials running simultaneously in the coming months.
Quintessence Biosciences’ Novel Approach to Cancer Therapy
Quintessence Biosciences is a biopharmaceutical company specializing in the development of novel protein-based therapeutics to fight cancer.